Capricor Therapeutics Advances Deramiocel BLA Review Ahead of August 2026 PDUFA Date

With Capricor Therapeutics' deramiocel facing an FDA PDUFA date of August 22, 2026, contract manufacturers and QA directors supporting allogeneic cell therapy programs should be stress-testing commercial-scale readiness now, not after approval. Phase 3 HOPE-3 data presented at the 2026 ASGCT Annual Meeting reinforced the therapy's clinical profile in DMD-associated cardiomyopathy and skeletal muscle decline, adding weight to an already active BLA review.

Deramiocel is an investigational allogeneic cell therapy targeting the dual pathology of Duchenne muscular dystrophy: progressive cardiac and skeletal muscle deterioration. The HOPE-3 findings, presented at the American Society of Gene and Cell Therapy Annual Meeting, extend earlier efficacy signals and arrive at a moment when the FDA is actively reviewing the biologics license application. For plant heads managing allogeneic platforms, the August timeline compresses the window for process validation completion and batch release protocol finalization under 21 CFR Part 211 and applicable biologics GMP frameworks.

Separately, Qihan Biotech received FDA IND clearance for QT-019C, an allogeneic, off-the-shelf CAR-T engineered to co-target CD19 and BCMA in autoimmune indications. Developed on the company's QUIET multiplexed gene editing platform, QT-019C is designed to eliminate surface T-cell receptor expression to mitigate graft-versus-host disease risk. A notable manufacturing implication: the therapy's intended compatibility with reduced or eliminated lymphodepleting preconditioning, if validated, could expand the eligible patient population and increase commercial demand projections for CDMOs building capacity around allogeneic CAR-T.

Elsewhere in the sector, CSL Canada confirmed the first Canadian patient received Hemgenix (etranacogene dezaparvovec) outside a clinical trial at London Health Sciences Centre in Ontario, marking a commercial administration milestone for AAV5-based gene therapy in hemophilia B. Grace Sciences also reported interim phase 1/2/3 data for GS-100, an ICV AAV9 gene therapy for NGLY1 Deficiency, showing early motor and cognitive improvements across seven pediatric patients in four dose cohorts, with a dose-dependent safety profile informing pivotal dose selection. Kyverna Therapeutics' miv-cel continued clinical evaluation in myasthenia gravis under the KYSA-6 trial, with phase 2 findings discussed by Stanford neurology faculty.

The August 22 PDUFA date for deramiocel represents the nearest hard regulatory checkpoint across this pipeline cluster, and QA leads at facilities supporting allogeneic cell therapy manufacturing should confirm sterility assurance protocols and batch documentation are aligned with BLA commitments before that date arrives.

Source: CGTLive via cgtlive.com, May 20, 2026.